RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Armata Pharmaceuticals - Stock

Armata Pharmaceuticals P/S 2024

Armata Pharmaceuticals P/S

21.43

Ticker

ARMP

ISIN

US04216R1023

WKN

A2PKLC

As of Jun 25, 2024, Armata Pharmaceuticals's P/S ratio stood at 21.43, a 79.33% change from the 11.95 P/S ratio recorded in the previous year.

The Armata Pharmaceuticals P/S history

Armata Pharmaceuticals Aktienanalyse

What does Armata Pharmaceuticals do?

Armata Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of therapies for severe bacterial infections. The company was founded in California in 2009 and has been listed on the NASDAQ stock exchange since 2019. The founders of Armata Pharmaceuticals Inc. recognized that antibiotic resistance is a growing problem and that it is crucial to develop new therapies to address the challenges in the fight against bacterial infections. The company's business model is based on the discovery and development of bacteriophage therapies. Bacteriophages are natural viruses that can infect and destroy bacteria. Armata Pharmaceuticals Inc. has two main divisions: Armatavax, which focuses on the development of vaccines against bacterial infections, and Armatamab, which works on the development of monoclonal antibodies that express bacteriophage genes and thus have higher efficacy in combating bacteria. The company is currently developing several products based on bacteriophage therapies. The main product is AR-301, a monoclonal antibody designed to treat Staphylococcus infections causing pneumonia. AR-301 is in phase IIb study and has shown promising results. The company also has several other products in the pipeline, including AR-105 against Pseudomonas aeruginosa infections, AR-201 against Acinetobacter baumannii infections, and AR-401 against Enterobacteriaceae infections. Armata Pharmaceuticals Inc. works closely with various academic institutions and research facilities to explore the potential of bacteriophage therapies and develop new products. The company has acquired a number of patents and intellectual property in this area. To bring its products to market, Armata Pharmaceuticals Inc. has formed strategic partnerships with various companies, including AmpliPhi Biosciences, the United States Department of Defense's Drug Agency (DTRA), and Synthetic Biologics. These partnerships enable the company to lower its development costs while increasing access to a broader market. In summary, Armata Pharmaceuticals Inc. is an innovative biopharmaceutical company specializing in the development of bacteriophage therapies for severe bacterial infections. The company has a strong pipeline of products in various stages of development and is actively working to improve its technology and strengthen its market position. Through its partnerships and commitment to cutting-edge research, Armata Pharmaceuticals Inc. ensures that it is well-positioned to address the challenges in the fight against antibiotic resistance. Armata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Armata Pharmaceuticals's P/S Ratio

Armata Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Armata Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Armata Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Armata Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Armata Pharmaceuticals Stock

What is the price-to-earnings ratio of Armata Pharmaceuticals?

The price-earnings ratio of Armata Pharmaceuticals is currently 21.43.

How has the price-earnings ratio of Armata Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Armata Pharmaceuticals has increased by 79.33% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Armata Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Armata Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Armata Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Armata Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Armata Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Armata Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Armata Pharmaceuticals?

Some factors that influence the price-earnings ratio of Armata Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Armata Pharmaceuticals pay?

Over the past 12 months, Armata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Armata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Armata Pharmaceuticals?

The current dividend yield of Armata Pharmaceuticals is .

When does Armata Pharmaceuticals pay dividends?

Armata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Armata Pharmaceuticals?

Armata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Armata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Armata Pharmaceuticals located?

Armata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Armata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Armata Pharmaceuticals from 6/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/25/2024.

When did Armata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/25/2024.

What was the dividend of Armata Pharmaceuticals in the year 2023?

In the year 2023, Armata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Armata Pharmaceuticals pay out the dividend?

The dividends of Armata Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Armata Pharmaceuticals

Our stock analysis for Armata Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Armata Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.